[1]
|
Seidah, N.G., Benjamet, S., Wickham, et al. (2003) The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1(NARC-1): Liver Regenersation and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. https://doi.org/10.1073/pnas.0335507100
|
[2]
|
Humphries, S.E., Whittall, R.A., Hubbart, C.S., et al. (2006) Genetic Causes of Familial Hypercholesterolaemia in Patients in the UK: Relation to Plasma Lipid Levels and Coronary Disease Risk. Journal of Medical Genetics, 43, 943-949. https://doi.org/10.1136/jmg.2006.038356
|
[3]
|
Akram, O.N., Bermier, A., Petrides, F., et al. (2010) Beyond LDL Cholesterol, a New Role for PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1279-1281. https://doi.org/10.1161/ATVBAHA.110.209007
|
[4]
|
Maxime, D., Jadwiga, M.W., Ahmed, Z., et al. (2012) Gene Inactivation of Proprotein Convertase subtiIisir/Kex in Type 9 Reduces Atherosclerosis in Mice. Circulation, 125, 894-901.
https://doi.org/10.1161/CIRCULATIONAHA.111.057406
|
[5]
|
Melvin, J.C., Holmberg, L., Rohmann, S., et al. (2013) Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses. Journal of Cancer Epi-demiology, 2013, Article ID: 823849. https://doi.org/10.1155/2013/823849
|
[6]
|
Bake, A.E. and Nelson, E.R. (2016) The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Hormones and Cancer, 7, 219-228. https://doi.org/10.1007/s12672-016-0262-5
|
[7]
|
Leignadier, J., Dalenc, F., Poirot, M., et al. (2017) Improving the Efficacy of Hormone Therapy in Breast Cancer: The Role of Cholesterol Metabolism in SERM-Mediated Autophagy, Cell Differentiation and Death. Biochemical Pharmacology, 15, 18-28. https://doi.org/10.1016/j.bcp.2017.06.120
|
[8]
|
Kitahara, C.M., de Gonzalez, A.B., Freedman, N.D., et al. (2011) Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea. Journal of Clinical Oncology, 29, 1592-1598. https://doi.org/10.1200/JCO.2010.31.5200
|
[9]
|
Hong, S.H., Cha, J.M., Lee, J.I., et al. (2014) Association of Hyper-LDL Cholesterolmia with Increased Risk of Colorectal Adenoma. Hepatogastroenterology, 61, 1588-1549.
|
[10]
|
Agnoli, C., Grioni, S., Sieri, S., et al. (2014) Colorectal Cancer Risk and Dyslipidemia: A Case-Cohort Study Nested in an Italian Multicentre Cohort. Cancer Epidemiology, 38, 144-151. https://doi.org/10.1016/j.canep.2014.02.002
|
[11]
|
Stadler, S.C., Hacker, U. and Burkhardt, R. (2016) Cholestero Metabolism and Breast Cancer. Current Opinion in Lipidology, 27, 200-201. https://doi.org/10.1097/MOL.0000000000000285
|
[12]
|
Morris, D.L., Borhani, N.O., Fitzsimons, E., et al. (2013) Serum Cholesterol and Cancer in the Hypertension Detection and Follow-Up Program. Cancer, 52, 1754-1759.
https://doi.org/10.1002/1097-0142(19831101)52:9<1754::AID-CNCR2820520933>3.0.CO;2-J
|
[13]
|
刘业六, 钱海鑫, 秦磊, 等. 血脂相与乳腺癌远处转移的关系[J]. 中华肿瘤杂志, 2012, 34(2): 129-131.
|
[14]
|
Kumar, S. and Vaux, D.L. (2002) Apoptosis. A Cinderella Caspase Takes Center Stage. Science, 297, 1290-1291.
https://doi.org/10.1126/science.1076118
|
[15]
|
Ranheim, T., Mattingsdal, M., Lindvall, J.M., et al. (2008) Ge-nome-Wide Expression Analysis of Cells Expressing Gain of Function Mutant D374Y-PCSK9. Cellular Physiology, 217, 459-467. https://doi.org/10.1002/jcp.21519
|
[16]
|
Demidyuk, V., Shubin, A.V., Gasanov, E.V., et al. (2013) Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios. PLoS ONE, 8, e55752.
https://doi.org/10.1371/journal.pone.0055752
|
[17]
|
Lan, H., Pang, L., Smith, M.M., et al. (2010) Proprotein Con-vertase Subtilisin/Kexin Type 9(PCSK9) Affects Gene Expression Pathways beyond Cholesterol Metabolism in Liver Cells. Journal of Cellular Physiology, 224, 273-281.
https://doi.org/10.1002/jcp.22130
|
[18]
|
Poirier, S., Mayer, G., Benjannet, S., et al. (2008) The Proprotein Con-vertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. Journal of Biological Chemistry, 283, 2363-2372. https://doi.org/10.1074/jbc.M708098200
|
[19]
|
Seidah, N.G. and Prat, A. (2012) The Biology and Therapeutic Targeting of the Proprotein Convertases. Nature Reviews Drug Discovery, 11, 367-383. https://doi.org/10.1038/nrd3699
|
[20]
|
Dive, C. and Hickman, J.A. (2001) Drug-Target Interactions: Only the First Step in the Commitment to a Programmed Cell Death. British Journal of Cancer, 64, 192-196. https://doi.org/10.1038/bjc.1991.269
|
[21]
|
Gross, A., et al. (1999) BCL-2 Family Members and the Mitochondria in Apoptosis. Genes & Development, 13, 1899-1911. https://doi.org/10.1101/gad.13.15.1899
|
[22]
|
Ming, X.P., Ji, W.B., Peng, F.Z., et al. (2015) PCSK9 Regulates Apoptosis in Human Neuroglioma U251 Cells via Mitochondrial Signaling Pathways. International Journal of Clinical and Experimental Pathology, 8, 2787-2794.
|
[23]
|
Bingham, B., Shen, R., Kotnis, S., et al. (2006) Proapoptotic Effects of NARC1 (= PCSK9), the Gene Encoding a Novel Serine Pro-teinase. Cytometry A, 69, 1123-1131. https://doi.org/10.1002/cyto.a.20346
|
[24]
|
Sun, X., Essalmani, R., Day, R., et al. (2012) Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver. Neoplasia, 14, 1122-1131. https://doi.org/10.1593/neo.121252
|